Oncolytic virus therapy using genetically engineered herpes simplex viruses
Oncolytic virus therapy using genetically engineered herpes simplex viruses
复制标题
DOI：
10.1111/j.1749-0774.2002.tb00109.x
复制
发表时间：
2002-08
期刊：
影响因子：
4.3
通讯作者：
T. Todo
中科院分区：
文献类型：
--
作者：
T. Todo
近年来，越来越多的溶瘤病毒载体被开发用于癌症治疗。1型单纯疱疹病毒（HSV-1）载体是特别有用的，因为它们可以被遗传工程化以在肿瘤细胞中高度选择性地复制和扩散，并且还可以表达多种外源转基因。这些载体可以在多种肿瘤类型中表现出细胞病变效应而不损伤正常组织，在肿瘤内提供扩增的基因递送，并诱导特异性抗肿瘤免疫。多种重组HSV-1载体已在脑肿瘤和其他癌症患者中进行了测试，这表明在包括脑在内的人体器官中安全施用可复制HSV-1载体的可行性。目前采用不同的方法来提高溶瘤HSV-1治疗的功效，包括通过对现有安全载体进行进一步基因工程改造开发新一代载体，与免疫基因治疗组合，以及与常规治疗组合。溶瘤病毒治疗是一种有前途的治疗方式，等待在不久的将来成为癌症患者的重要治疗选择。
An increasing number of oncolytic virus vectors has been developed lately for cancer therapy. Herpes simplex virus type 1 (HSV-1) vectors are particularly useful, because they can be genetically engineered to replicate and spread highly selectively in tumor cells and can also express multiple foreign transgenes. These vectors can manifest cytopathic effect in a wide variety of tumor types without damaging normal tissues, provide amplied gene delivery within the tumor, and induce specific antitumor immunity. Multiple recombinant HSV-1 vectors have been tested in patients with brain tumors and other cancers, which showed the feasibility of administering replication-competent HSV-1 vectors safely in human organs including the brain. Different approaches are currently undertaken to improve the efficacy of oncolytic HSV-1 therapy which include development of new generation vectors via further genetic engineering of existing safe vectors, combination with immune gene therapy, and combination with conventional therapies. Oncolytic virus therapy is a promising therapeutic modality that awaits establishing as an important treatment option for cancer patients in the near future.